Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats

Archives of Pharmacal Research

Volumn 32, Issue 1, 2009, Pages 133-138

  Li, Cheng ^a,b   Li, Xiuguo ^a   Choi, Jun Shik ^b  

^a YANBIAN UNIVERSITY   (China)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; CYP3A; Etoposide; Kaempferol; P gp; Pharmacokinetics; Rats

Indexed keywords

CYTOCHROME P450 3A; ETOPOSIDE; GLYCOPROTEIN P; KAEMPFEROL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; LIVER CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; ETOPOSIDE; INJECTIONS, INTRAVENOUS; INTESTINES; KAEMPFEROLS; LIVER; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 59449092342     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-009-1127-z     Document Type: Article

References (22)

1. J. Carcel-Trullols F. Torres-Molina A. Araico A. Saadeddin J. E. Peris 2004 Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide Cancer Chemother. Pharmacol. 54 153 160
2. P. I. Clark M. L. Slevin 1987 The clinical pharmacology of etoposide and teniposide Clin. Pharmacokinet. 12 223 252
3. T. Kawashiro K. Yamashita X. J. Zhao E. Koyama M. Tani K. Chiba T. Ishizaki 1998 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes J. Pharmacol. Exp. Ther. 286 1294 1300
4. R. P. Keller H. J. Altermatt P. Donatsch H. Zihlmann J. A. Laissue P. C. Hiestand 1992 Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity Int. J. Cancer. 51 433 438
5. B. L. Leu J. D. Huang 1995 Inhibition of intestinal P-glycoprotein and effects on etoposide absorption Cancer Chemother. Pharmacol. 35 432 436
6. X. Li J. K. Yun J. S. Choi 2007 Effects of morin on the pharmacokinetics of etoposide in rats Biopharm. Drug Dispos. 28 151 156
7. K. H. Miean S. Mohamed 2001 Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants J. Agric. Food Chem. 49 3106 3612
8. M. Ofer S. Wolffram A. Koggel H. Spahn-Langguth P. Langguth 2005 Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur. J. Pharm. Sci. 25 263 271
9. D. Pal A. K. Mitra 2006 MDR- and CYP3A4-mediated drugherbal interactions Life Sci. 78 2131 2145
10. J. Patel B. Buddha S. Dey D. Pal A. K. Mitra 2004 In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity Am. J. Ther. 11 262 277
11. Y. Piao S. C. Shin J. S. Choi 2008 Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats Biopharm. Drug Dispos. 29 245 249
12. M. V. Relling J. Nemec E. G. Schuetz J. D. Schuetz F. J. Gonzalez K. R. Korzekwa 1994 O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 Mol. Pharmacol. 45 352 358
13. H. F. Stahelin A. von Wartburg 1991 The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture Cancer Res. 51 5 15
14. L. Sutherland T. Ebner B. Burchell 1993 The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs Biochem. Pharmacol. 45 295 301
15. D. Turgeon J. S. Carrier E. Levesque D. W. Hum A. Belanger 2001 Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members Endocrinology. 142 778 787
16. J. M. van Maanen J. de Vries D. Pappie E. van den Akker V. M. Lafleur J. Retel J. van der Greef H. M. Pinedo 1987 Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213) Cancer Res. 47 4658 4662
17. V. J. Wacher L. Salphati L. Z. Benet 2001 Active secretion and enterocytic drug metabolism barriers to drug absorption Advanced Drug Delivery Reviews. 46 89 102
18. Y. Wang J. Cao S. Zeng 2005 Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin J. Pharm Pharmacol. 57 751 758
19. Y. Wang J. Cao S. Zeng G. Inramonti A. Donati E. Chieli 2004 Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2 Life Sci. 76 293 302
20. P. B. Watkins 1997 The barrier function of CYP3A4 and P-glycoprotein in the small bowel Advanced Drug Delivery Reviews. 27 161 170
21. A. J. Wozniak W. E. Ross 1983 DNA damage as a basis for 4-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity Cancer Res. 43 120 124
22. F. F. Zhang Y. F. Zheng H. J. Zhu X. Y. Shen X. Q. Zhu 2006 Effects of kaempferol and quercetin on cytochrome 450 activities in primarily cultured rat hepatocytes Zhejiang Da Xue Xue Bao Yi Xue Ban. 35 18 22